Hana Pharm

하나제약 · 293480

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$117.3M (₩161.9B)

Overview

Hana Pharm makes prescription medicines, including opioid painkillers used for severe pain and anaesthetic drugs used in surgical settings, supplied to hospitals and clinics across South Korea.

Its broader portfolio spans cardiovascular, digestive, neurological, and dermatological medicines, with several hundred products listed on Korea's national health-insurance reimbursement scheme. Listed on KOSPI, Korea's main stock exchange, the company operates multiple manufacturing facilities in Hwaseong, Gyeonggi Province, alongside a dedicated research-and-development centre in Pangyo.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$173.6M

▲ +6.3% YoY

Operating profit · FY2025

US$18.7M

▲ +2.6% YoY

Net income · FY2025

US$6.4M

▼ −58.7% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$162.6M(₩224.5B)	US$163.3M(₩225.3B)	US$173.6M(₩239.5B)
Operating profit	US$19.6M(₩27B)	US$18.2M(₩25.2B)	US$18.7M(₩25.8B)
Net income	US$16.2M(₩22.3B)	US$15.4M(₩21.3B)	US$6.4M(₩8.8B)

Revenue

FY2023US$162.6M
FY2024US$163.3M
FY2025US$173.6M

Operating profit

FY2023US$19.6M
FY2024US$18.2M
FY2025US$18.7M

Net income

FY2023US$16.2M
FY2024US$15.4M
FY2025US$6.4M

Key ratios (FY2025)

ROE

2.8%

Debt/Eq

33.4%

Op. margin

10.8%

Net margin

3.7%

Rev. YoY

▲ +6.3%

Why it matters

The company runs three manufacturing plants in Hwaseong, including a dedicated injectable-drug facility, and a separate R&D centre in Pangyo, giving it an integrated domestic production and research footprint.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?